[HTML][HTML] Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab′ antibody
N Poirier, C Mary, N Dilek, J Hervouet, D Minault… - American Journal of …, 2012 - Elsevier
Antagonist anti-CD28 antibodies prevent T cell costimulation and differentiate from CTLA4Ig
since they cannot block CTLA-4 and PDL-1 coinhibitory signals. They demonstrated efficacy
in suppressing effector T cells while enhancing regulatory T cells function and immune
tolerance. However, anti-CD28 antibodies devoid of immunotoxicity and with a good
pharmacokinetic profile have not yet been developed. Here, we describe FR104, a novel
humanized pegylated anti-CD28 Fab′ antibody fragment presenting a long elimination half …
since they cannot block CTLA-4 and PDL-1 coinhibitory signals. They demonstrated efficacy
in suppressing effector T cells while enhancing regulatory T cells function and immune
tolerance. However, anti-CD28 antibodies devoid of immunotoxicity and with a good
pharmacokinetic profile have not yet been developed. Here, we describe FR104, a novel
humanized pegylated anti-CD28 Fab′ antibody fragment presenting a long elimination half …